215 related articles for article (PubMed ID: 33808900)
1. Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models.
Kopczynski M; Statkiewicz M; Cybulska M; Kuklinska U; Unrug-Bielawska K; Sandowska-Markiewicz Z; Grochowska A; Gajewska M; Kulecka M; Ostrowski J; Mikula M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808900
[TBL] [Abstract][Full Text] [Related]
2. Novel engineered TRAIL-based chimeric protein strongly inhibits tumor growth and bypasses TRAIL resistance.
Rozga P; Kloska D; Pawlak S; Teska-Kaminska M; Galazka M; Bukato K; Pieczykolan A; Jaworski A; Molga-Kaczmarska A; Kopacz A; Badyra B; Kachamakova-Trojanowska N; Zolnierkiewicz O; Targosz-Korecka M; Poleszak K; Szymanik M; Zerek B; Pieczykolan J; Jozkowicz A; Grochot-Przeczek A
Int J Cancer; 2020 Aug; 147(4):1117-1130. PubMed ID: 31863596
[TBL] [Abstract][Full Text] [Related]
3. AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L.
Pieczykolan JS; Kubiński K; Masłyk M; Pawlak SD; Pieczykolan A; Rózga PK; Szymanik M; Gałązka M; Teska-Kamińska M; Żerek B; Bukato K; Poleszak K; Jaworski A; Strożek W; Świder R; Zieliński R
Invest New Drugs; 2014 Dec; 32(6):1155-66. PubMed ID: 25182378
[TBL] [Abstract][Full Text] [Related]
4. Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC; Buchanan FG; Cheng D; Solomon LR; Xiao Y; Xue J; Tahir SK; Smith ML; Zhang H; Widomski D; Abraham VC; Xu N; Liu Z; Zhou L; DiGiammarino E; Lu X; Rudra-Ganguly N; Trela B; Morgan-Lappe SE
Cancer Res; 2021 Jun; 81(12):3402-3414. PubMed ID: 33687950
[TBL] [Abstract][Full Text] [Related]
5. Activity and rational combinations of a novel, engineered chimeric, TRAIL-based ligand in diffuse large B-cell lymphoma.
Piechna K; Żołyniak A; Jabłońska E; Noyszewska-Kania M; Szydłowski M; Żerek B; Kulecka M; Rumieńczyk I; Mikula M; Juszczyński P
Front Oncol; 2022; 12():1048741. PubMed ID: 36387080
[TBL] [Abstract][Full Text] [Related]
6. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
7. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
8. Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.
Prigozhina TB; Szafer F; Aronin A; Tzdaka K; Amsili S; Makdasi E; Shani N; Dranitzki Elhalel M
Cancer Lett; 2017 Aug; 400():99-109. PubMed ID: 28455246
[TBL] [Abstract][Full Text] [Related]
9. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
10. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
11. Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
Sun T; Zhu T; Liang X; Yang S; Zhao R
Med Sci Monit; 2018 Apr; 24():2550-2561. PubMed ID: 29695684
[TBL] [Abstract][Full Text] [Related]
12. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy.
Singh D; Tewari M; Singh S; Narayan G
Future Oncol; 2021 Feb; 17(5):581-596. PubMed ID: 33401962
[TBL] [Abstract][Full Text] [Related]
14. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.
Park KJ; Lee SH; Kim TI; Lee HW; Lee CH; Kim EH; Jang JY; Choi KS; Kwon MH; Kim YS
Cancer Res; 2007 Aug; 67(15):7327-34. PubMed ID: 17671202
[TBL] [Abstract][Full Text] [Related]
15. Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines.
Engelsgjerd S; Kunnimalaiyaan S; Kandil E; Gamblin TC; Kunnimalaiyaan M
PLoS One; 2019; 14(3):e0213776. PubMed ID: 30870485
[TBL] [Abstract][Full Text] [Related]
16. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
17. Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells.
Rozanov DV; Savinov AY; Golubkov VS; Rozanova OL; Postnova TI; Sergienko EA; Vasile S; Aleshin AE; Rega MF; Pellecchia M; Strongin AY
Mol Cancer Ther; 2009 Jun; 8(6):1515-25. PubMed ID: 19509255
[TBL] [Abstract][Full Text] [Related]
18. Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer.
She T; Shi Q; Li Z; Feng Y; Yang H; Tao Z; Li H; Chen J; Wang S; Liang Y; Cheng J; Lu X
Theranostics; 2021; 11(9):4281-4297. PubMed ID: 33754061
[TBL] [Abstract][Full Text] [Related]
19. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
[TBL] [Abstract][Full Text] [Related]
20. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Qiu F; Hu M; Tang B; Liu X; Zhuang H; Yang J; Hua ZC
Sci Rep; 2013 Dec; 3():3565. PubMed ID: 24356445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]